|
Spastic Paraplegia 42, Autosomal Dominant
|
0.710 |
GeneticVariation
|
disease |
BEFREE |
A missense mutation in SLC33A1, which encodes the acetyl-CoA transporter, causes autosomal-dominant spastic paraplegia (SPG42).
|
19061983 |
2008 |
|
Spastic Paraplegia
|
0.110 |
Biomarker
|
disease |
BEFREE |
SLC33A1 is associated with neurodegenerative disorders such as sporadic amyotrophic lateral sclerosis (ALS) and Spastic Paraplegia 42, in the Chinese population.
|
23506891 |
2013 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The AT1 receptor promotes various intracellular signaling pathways resulting in hypertension, endothelial dysfunction, vascular remodeling and end organ damage.
|
28527699 |
2017 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the BP response to AT1 receptor blockers varied significantly among individuals with hypertension.
|
24131669 |
2014 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that chronic elevation of Ang IV in the brain can induce hypertension that can be treated with angiotensin II AT1 receptor antagonists.
|
15117826 |
2004 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we discuss the role of renin-angiotensin system (RAS) in hypertension; the current gene delivery/gene transfer systems and the RAS as a target for gene therapy to treat hypertension; the successful use of retroviral vectors to deliver antisense to the AT1 receptor (AT1-AS) to prevent the development of hypertension and cardiovascular pathophysiology; the potential use of the viral vectors for the reversal of hypertension; and the future of antisense gene therapy and potential advantages and limitations of this regimen in the treatment and/or control of hypertension.
|
10779083 |
2000 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Previous studies have shown that angiotensin II AT1 receptor gene (AT1R) polymorphisms are associated with the risk for hypertension.
|
25990648 |
2015 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The A1166C polymorphism of the AT1 receptor gene (AT1R/A1166C) is associated with hypertension in Caucasians, but not in Japanese.
|
15492474 |
2004 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We detected no association of the AT1 receptor polymorphism with hypertension, but a trend towards a decreased prevalence of the 1166C allele among hypertensive patients with a late age at diagnosis (> or = 50 years) was observed.
|
9431842 |
1997 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The first paper on the genetic role of the AT1 gene in human hypertension has just been published.
|
7743157 |
1995 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our data show that spinal ionotropic glutamatergic and AT1 receptors contribute to increased rSNA in the 2K1C model, leading to the maintenance of hypertension; however, the participation of spinal AT1 receptors seems to be especially important in the establishment of sympathoexcitation in this model.
|
29935157 |
2018 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The present meta-analysis suggests that the AT(1) receptor 1166 AC/CC genotype is associated with susceptibility to hypertension in the Chinese population.
|
20223791 |
2010 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Candesartan, an AT(1) receptor antagonist, has been reported to have no association with persistent cough in subjects with hypertension, but there has been no study on the safety of its administration to hypertensive patients with symptomatic asthma.
|
11457745 |
2001 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that the AGT and AT1 receptor genes are not major genetic determinants of hypertension associated with NIDDM in this population, although we can not exclude the possibility that these loci make a minor contribution in a polygenic context.
|
9218178 |
1997 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Purinergic P2Y6 receptors heterodimerize with angiotensin AT1 receptors to promote angiotensin II-induced hypertension.
|
26787451 |
2016 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We have investigated whether the A1166C polymorphism of the angiotensin II type 1 (AT1) receptor gene modulates the effects of angiotensin II on collagen type I turnover and myocardial stiffness in hypertension.
|
14597852 |
2003 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The finding of polymorphic sites in the functional promoter of the human AT1 locus will be beneficial to the study of the role of the AT1 receptor gene in hypertension and other cardiovascular diseases.
|
10738546 |
1999 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
To address the hypothesis that increased myocardial AT1 receptor density causes cardiac hypertrophy apart from high blood pressure we developed a transgenic rat model which expresses the human AT1 receptor under the control of the alpha-myosin heavy-chain promoter specifically in the myocardium.
|
11692158 |
2001 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Therefore, we conducted an association study between A1166C variants of the AT1 receptor gene and hypertension in the Japanese population.
|
12627871 |
2003 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that enhanced constrictive responsiveness of renal afferent arterioles (Af-Art) to angiotensin II (ANG II) mediated by ANG II type 1 (AT1) receptors contributes to the development of hypertension in diabetes.
|
28842434 |
2017 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The uremic environment seems to dominate over previously reported actions of high blood pressure and cholesterol to enhance leukocyte Angiotensin II AT1 receptor expression.
|
21640098 |
2011 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
1.Using a nested case-control study of 661 non-institutionalized elderly (> or = 60 years) residents of Dubbo, New South Wales, Australia, the aim of this study is to determine whether the A1166C polymorphism of the angiotensin II type I (AT1) receptor gene is associated with hypertension in the elderly.2.
|
10405780 |
1999 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggested that in vivo expression of h-chymase caused mild hypertension (AT1 receptor-dependent) with left ventricular hypertrophy (partially AT1 receptor-dependent), and also chronic inflammatory changes (AT1 receptor-independent).
|
14620933 |
2003 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that increased activation of central AT-1 receptors, perhaps those located at sites involved in AVP release from the posterior pituitary gland, plays a role in the hypertension in RA+ mice.
|
9815152 |
1998 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The detrimental actions of the AT1 receptor (AT1R) in hypertension and vascular injury, myocardial infarction and brain ischemia are well established.
|
24414230 |
2014 |